Kyntra Bio (KYNB)
NASDAQ:KYNB
Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.32
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.32
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$4.85 - $12.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.76K
Market Cap
$27.37M
Enterprise Value-$9.07M
Total Cash (Recent Filing)$87.24M
Total Debt (Recent Filing)$19.25M
Price to Earnings (P/E)0.2
Beta0.86
Next Earnings
Aug 10, 2026EPS Estimate
-3.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.56
Shares Outstanding4,048,112
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-0.33
Enterprise Value/Revenue-1.22
Enterprise Value/Gross Profit-2.70
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$36.50Price Target Upside398.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-13.89
Revenue Forecast (FY)$5.15M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Multi-year RunwayA ~$100M liquidity stockpile and completed China divestiture proceeds materially extend funding for clinical programs through 2028. This reduces near-term financing pressure, allowing management to execute trials and endpoint-driven development without immediate dilution or partner dependency.
Zero Reported Debt And Returning Revenue GrowthZero financial leverage combined with improving revenue trends strengthens financial flexibility versus peers. With limited interest burden and modest revenue growth, management can prioritize R&D spend and trial execution while having greater optionality for partnerships or selective financing.
Clinically Validated Signals And Biomarker PotentialDemonstrated efficacy signals, a potential companion diagnostic (FG-3180) to enrich responders, and a validated neutropenia mitigation strategy improve the structural probability of successful registrational trials. These durable clinical advantages support differentiated development and de-risk dose/safety execution.
Bears Say
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow means ongoing burn from operations, forcing reliance on financing, asset sales, or partnerships. Over time this can dilute shareholders, constrain program funding choices, and increase execution risk if cash runway shortens or fundraising terms worsen.
Negative Shareholders' Equity And Balance-sheet FragilityNegative equity signals prior losses have eroded the capital cushion, limiting the company's ability to absorb setbacks. It can complicate access to credit, worsen financing terms, and amplify solvency risk if clinical or commercial timelines slip, making long-term funding less predictable.
Nasdaq Listing Compliance RiskA sustained listing compliance issue is a structural governance and capital-markets risk. Potential delisting or forced transfer to another tier could reduce liquidity, raise cost of capital, and impair investor/partner confidence, complicating long-term financing and strategic transactions.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $4.85 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $27.37M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Aug 10, 2026 which is in 58 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on May 11, 2026. The company reported -$3.76 earnings per share for the quarter, missing the consensus estimate of -$3.355 by -$0.405.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.27.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,048,112 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of -$3.76 in its last earnings report, missing expectations of -$3.355. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$36.50
▲(398.63% Upside)
Technical Analysis
Ownership Overview
1.76% Insiders
22.61% Mutual Funds
10.71% Other Institutional Investors
61.06% Public Companies and
Individual Investors